Rani reports 90% success in preclinical RaniPill HC studies; Phase 1 of adalimumab planned

Rani Therapeutics Holdings, Inc.

RaniPill HC delivered teriparatide in 18/20 administrations across two canine studies, a 90% cumulative success rate.
Payload increased to up to 20 mg, enabling oral delivery of 90+ additional drug candidates.
Fe57 study showed drug absorption comparable to subcutaneous injection.
Next milestone: initiate Phase 1 trial of RT-105 (adalimumab) using RaniPill HC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.